Tofacitinib Helpful Before or After Biologic DMARD Therapy: AnalysisTofacitinib Helpful Before or After Biologic DMARD Therapy: Analysis

The oral JAK inhibitor tofacitinib (Xeljanz, Pfizer) reduces the signs and symptoms of rheumatoid arthritis (RA) when used before or after a biologic disease-modifying antirheumatic drug (bDMARD), although responses are greater in bDMARD-naive patients, according to an analysis of pooled trial data funded by the drug maker. Reuters Health Information
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Rheumatology News Source Type: news